Biotech's New Normal
Challenges and Opportunities
In this virtual event, BioPharma Dive journalists will discuss the emerging biotech ecosystem with executives, venture investors and industry experts, building on our award-winning coverage of the sector.
Over three panels, we will explore the financial and operational challenges facing early-stage drug companies and their backers. Attendees will also get to hear the latest on the scientific catalysts that are fueling the formation of new startups.
Who Should Attend?
- Executives and employees at early-stage biotech companies
- Partners and associates at biotech venture capital firms
- Executives and employees at pharmaceutical company venture arms, or who are involved in private company business development
- Executives and employees at biotech incubators
Reserve Your Seat
Session Information
Financing Biotech Startups
This panel discussion will feature biotech executives and venture investors discussing the current environment for funding new drug companies, both privately and as those companies advance toward public markets.
Building Biotechs To Last
While the biotech sector has stabilized after last year’s downturn, companies still face a difficult environment. How is that affecting their strategy and plans for growth? Join this panel discussion to hear from executives navigating these challenges.
New Areas of Research Momentum
Scientific advances are opening up opportunities for new types of medicines, such as for those that treat diseases of the brain and immune system. In this panel discussion, you’ll hear from venture investors tasked with making bets on promising research and from drug company executives tasked with turning that potential into reality.
